Dr Johnson stated: "The appointment of Dr Peoples represents a significant milestone in development of our clinical programs at Quantum. Dr Peoples has had extensive experience in overseeing clinical trials including those with cancer vaccines such as ours and his expertise will be invaluable moving forward in clinical development. We look forward to working with Dr Peoples on this important phase of drug development."
Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies.
Dr Peoples stated: "I am excited by the opportunity to assist Quantum with their clinical development program as we share the belief that the recruitment of the patient's own immune system will be the next critical advance in the treatment of cancer."